Seham Health Care Foundation (SHECA)

Email

shecafoundation@gmail.com

Phone

T: +234 909 000 0123

Web

www.shecafoundation.org

Address

7 Olonode Street, Alagomeji, Yaba Lagos Lagos Nigeria
About Seham Health Care Foundation (SHECA)

The SHECA foundation is a not for profit organization dedicated to the development of public awareness, prevention and care for viral hepatitis and related cancer. These infection and related cancer are preventable through behavioural changes, risk reduction and vaccination. This foundation is dedicated to informing the public about disease prevention strategies, screening of disease for early detection and provision of diagnosis and support for care.

These diseases are mangable and at best curable if detected early and approrptiate actions taken. SHECA foundation derives satisfaction from being able to say we helped to save a life. The foundation structures for the set objectives through fund raised from well-meaning indiviudals, corporate organizations and donor funders.

The SHECA foundation was formally founded in April 2015, through low scale operations started in 2009. The foundation comprises of patients, healthcare practitioners, advocacy specialist and interested members of the public. Membership is voluntary and open to person 18 years and above.

Our strategy:

  1. To organize campaign program to reduce the incidence of hepatitis infection and related cancer in Nigeria using preventive health care.
  2. To assist in preventing the incidence of chronic liver disease.
  3. To conduct a prevalence survey for the use of public hepatitis control program.
  4. To solicit for funds and support in order to reduce the incidence of hepatitis and other related helath matters in Nigeria.
  5. To conduct free screening and immunize the negative enrolees.
  6. To promote learning and research of hepatitis in educational institutions.
  7. To provide health/medical support to the sick in the society.
  8. Enrolees who are hepatitis B or C positive will be linked to the nearest specialist at the referral centers. 

Sign up to receive updates from WHA

Name(Required)
I would like to hear about(Required)

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Hepatitis and PWID/harm reduction 

 

11:35 – 11:40  

Chair: WHO – Intro and set the scene.  

 

11:40 – 11:55  

Co-chair:  EMCDDA – Monitoring viral hepatitis elimination among PWID in Europe. 

 

11:55 – 12:00 

ID 29: Ema Pos (not yet registered) 

Title: If the mountain won’t come to Mohammed: lessons from a decentralized Infectious Disease consultation. 

 

12:05 – 12:10  

ID 152: Brian Conway (Registered in person) 

Title: Community Pop-up Clinic: Cascade of Care and HCV Treatment of Vancouver’s inner-city PWID Populations.

 

12:10 – 12:15 

ID 212: Jasmine West (not yet registered) 

Title: From lived experience to lived expertise: a syndemic approach. 

 

12:15 – 12:20 

ID: 299 Mercy Nyakowa (Registered in person) 

Title: HCV and HBV prevalence and associated risk factors among people who inject drugs (PWIDs) in Kenya 

 

12:20 – 12:25 

ID: 133 Nalinikanta Rajkumar (Registered in person) 

Title: Rapid regimen of HBV vaccination: Does it work for high risk groups?  

 

12:25 – 12:30 

Q&A and closing remarks   

tHIS

 

IS 

 

BEN’S

 

 

 

BIG 

 

 

TEST

effective case finding strategies

Supported by Vir Biotechnology, Inc

During this session you will hear from hepatitis Delta expert, Dr. Maria Buti, and a patient who has lived with hepatitis Delta in a panel discussion moderated by Dr. Carey Hwang, Chief Medical Officer (interim) of Vir Biotechnology. This panel will inform perspectives on patient needs, opportunities for enhanced screening, and strengthening linkages to care.

Session Agenda

14:40 – 14:45    

Panel overview and introductions facilitated by Dr Carey Hwang (Vir Biotechnology)

14:45 – 15:05   

Panel discussion: Dr Maria Buti (University Hospital Vall d’Hebron, Spain), Milanka Barbosa, Dr Carey Hwang (Chief Medical Officer interim), Vir Biotechnology

15:05 – 15:10    

Final remarks and close